Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulation

Cardiovascular Diabetology

Iichiro Shimomura²  Tohru Funahashi¹  Akihisa Imagawa²  Norikazu Maeda²  Tetsuyuki Yasuda²  Tetsuhiro Kitamura²  Junji Kozawa²  Masaya Yamaoka²  Yuya Fujishima²  Kana Inoue²  Takekazu Kimura²  Susumu Kashine²  Hirofumi Nagao²  Hitoshi Nishizawa²  Ayumu Hirata¹  Shiro Fukuda² 

[1] Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B, Yamada-oka, Suita 565-0871, Osaka, Japan;Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita 565-0871, Osaka, Japan

关键词: Eating behavior;    Vascular ultrasonography;    Systemic arteriosclerosis;    Adiponectin;    Visceral fat accumulation;    Type 2 diabetes;   

Others  :  1118918
DOI  :  10.1186/s12933-015-0174-7

 received in 2014-10-28, accepted in 2015-01-03,  发布年份 2015

【 摘 要 】

Background

Visceral fat accumulation is a major etiological factor in the progression of type 2 diabetes mellitus and atherosclerosis. We described previously visceral fat accumulation and multiple cardiovascular risk factors in a considerable number of Japanese non-obese subjects (BMI <25 kg/m²). Here, we investigated differences in systemic arteriosclerosis, serum adiponectin concentration, and eating behavior in type 2 diabetic patients with and without visceral fat accumulation.

Methods

The study subjects were 75 Japanese type 2 diabetes mellitus (age: 64.8 ± 11.5 years, mean ± SD). Visceral fat accumulation represented an estimated visceral fat area of 100 cm² using the bioelectrical impedance analysis method. Subjects were divided into two groups; with (n = 53) and without (n = 22) visceral fat accumulation. Systemic arteriosclerosis was scored for four arteries by ultrasonography. Eating behavior was assessed based on The Guideline for Obesity questionnaire issued by the Japan Society for the Study of Obesity.

Results

The visceral fat accumulation (+) group showed significantly higher systemic vascular scores and significantly lower serum adiponectin levels than the visceral fat accumulation (−) group. With respect to the eating behavior questionnaire items, (+) patients showed higher values for the total score and many of the major sub-scores than (−) patients.

Conclusions

Type 2 diabetic patients with visceral fat accumulation showed 1) progression of systemic arteriosclerosis, 2) low serum adiponectin levels, and 3) differences in eating behavior, compared to those without visceral fat accumulation. Taken together, the findings highlight the importance of evaluating visceral fat area in type 2 diabetic patients. Furthermore, those with visceral fat accumulation might need to undergo more intensive screening for systemic arteriosclerosis and consider modifying their eating behaviors.

【 授权许可】

   
2015 Fukuda et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hirata A, Kishida K, Nakatsuji H, Hiuge-Shimizu A, Funahashi T, Shimomura I: Metabolic syndrome correlates with polyvascular lesions detected by systemic vascular ultrasonography in Japanese people with type 2 diabetes. Diabetes Res Clin Pract 2012, 96:e26-9.
• [2]World Health Organization. Obesity and overweight; WHO Fact Sheet No311; 2013. [http://www.who.int/mediacentre/factsheets/fs311/en/index.html]
• [3]Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
• [4]Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY: Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-8.
• [5]Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-40.
• [6]Okauchi Y, Nishizawa H, Funahashi T, Ogawa T, Noguchi M, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y: Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care 2007, 30:2392-4.
• [7]Obata Y, Yamada Y, Kyo M, Takahi Y, Saisho K, Tamba S, Yamamoto K, Katsuragi K, Matsuzawa Y: Serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes. J Diabetes Investig 2013, 4:475-82.
• [8]Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-9.
• [9]Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-7.
• [10]Tsiros MD, Sinn N, Brennan L, Coates AM, Walkley JW, Petkov J, Howe PR, Buckley JD: Cognitive behavioral therapy improves diet and body composition in overweight and obese adolescents. Am J Clin Nutr 2008, 87:1134-40.
• [11]Hays NP, Bathalon GP, McCrory MA, Roubenoff R, Lipman R, Roberts SB: Eating behavior correlates of adult weight gain and obesity in healthy women aged 55–65 y. Am J Clin Nutr 2002, 75:476-83.
• [12]Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I: A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005, 28:451-3.
• [13]Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-92.
• [14]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
• [15]Hirata A, Kishida K, Hiuge-Shimizu A, Nakatsuji H, Funahashi T, Shimomura I: Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes. Atherosclerosis 2011, 219:623-9.
• [16]Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y: Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009, 204:288-92.
• [17]Examination Committee of Criteria for ‘Obesity Disease’ in JapanJapan Society for the Study of Obesity: New criteria for ‘obesity disease’ in Japan Circ J 2002, 66:987-92.
• [18]Després JP, Lamarche B: Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993, 6:137-59.
• [19]Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Metabolic syndrome. J Atheroscler Thromb 2008, 15:1-5.
• [20]Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I: Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:109. BioMed Central Full Text
• [21]Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 2012, 11:107. BioMed Central Full Text
• [22]Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I: Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb 2011, 18:592-5.
• [23]Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-9.
• [24]Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-6.
• [25]Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-8.
• [26]Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-63.
• [27]Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-70.
• [28]Fisman EZ, Tenenbaum A: Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014, 13:103. BioMed Central Full Text
• [29]Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G, Hu FB, Bacci S, Qi L, Trischitta V: Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol 2014, 13:130. BioMed Central Full Text
• [30]Wannamethee SG, Welsh P, Whincup PH, Sawar N, Thomas MC, Gudnarsson V, Sattar N: High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2011, 18:65-71.
• [31]Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T, Shimomura I: Increment and impairment of adiponectin in renal failure. Cardiovasc Res 2010, 86:471-7.
• [32]Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D, Reddy S, Woodward M: Obesity in Asia Collaboration: Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008, 9:53-61.
• [33]Nagao H, Kashine S, Nishizawa H, Okada T, Kimura T, Hirata A, Fukuda S, Kozawa J, Maeda N, Kitamura T, Yasuda T, Okita K, Hibuse T, Tsugawa M, Imagawa A, Funahashi T, Shimomura I: Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovasc Diabetol 2013, 12:88. BioMed Central Full Text
• [34]The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993, 329:977-86.
• [35]UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998, 352:837-53.
• [36]Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y: Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2001, 51:195-203.
• [37]Dirani M, Xie J, Fenwick E, Benarous R, Rees G, Wong TY, Lamoureux EL: Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci 2011, 52:4416-21.
• [38]Maghbooli Z, Pasalar P, Keshtkar A, Farzadfar F, Larijani B: Predictive factors of diabetic complications: a possible link between family history of diabetes and diabetic retinopathy. J Diabetes Metab Disord 2014, 13:55. BioMed Central Full Text
• [39]Kozuka C, Yabiku K, Sunagawa S, Ueda R, Taira S, Ohshiro H, Ikema T, Yamakawa K, Higa M, Tanaka H, Takayama C, Matsushita M, Oyadomari S, Shimabukuro M, Masuzaki H: Brown rice and its component, γ-oryzanol, attenuate the preference for high-fat diet by decreasing hypothalamic endoplasmic reticulum stress in mice. Diabetes 2012, 61(12):3084-93.
• [40]Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87(4):1409-39.
• [41]Fujioka S, Matsuzawa Y, Tokunaga K, Keno Y, Kobatake T, Tarui S: Treatment of visceral fat obesity. Int J Obes 1991, 15(Suppl 2):59-65.
• [42]Zhang C, Luo H, Gao F, Zhang CT, Zhang R. A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program. Acta Diabetol. 2014, Oct 1. [Epub ahead of print]